Skip to main content
OpenTrials
Completed

NCT Number: NCT04380714

Changes in the Consumption of Psychoactive Substances During Containment Linked to COVID-19

The SARS-CoV 2 pandemic started in China in December 2019, then reached France on January 24, 2020.

On March 14, France moved into phase 3 of the epidemic threshold with the implementation of containment measures on March 17 Measures were put in place by N.Belloubet (French Minister of Justice) from March 17, including suspension of visiting rooms and activities in detention.

Containment provides boredom and isolation with many potential consequences: sleep disturbance, anxiety, PTSD, depression, suicide, addictive behavior and violence.

However,prisoners have a higher prevalence of substance use disorders than the general population.

What will have been the impact of the confinement on the consumption of psychoactive substances by prisoners at the Villeneuve Les Maguelone prison.

* Anonymous questionnaire from the start * Collection of socio-demographic data * Collection of consumption data before and during containment * Collection of monitoring data

Completed

Looking for future studies?

Notify Me

Key information

Conditions

People Incarcerated COVID-19 Coronaviridae Infections Coronavirus Infections Infections Lung Diseases Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

UH Montpellier

Montpellier, 34295, France

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Men incarcerated at Villeneuve Les Maguelone prison
  • On a given date (May 12)
  • Major
  • French speaking
  • non illiterate

Exclusion criteria

  • minors
  • patients refusing
  • non-French speaking
  • illiterate

Treatment and study plan

Primary outcomes

  1. percentage changes in the consumption of psychoactive substances

    Time frame: 1 day

    percentage changes in the consumption of psychoactive substances

Secondary outcomes

  1. Assessment of the level of stress

    Time frame: 1 day

    Assessment of the level of stress by self-administered questionnaire before / during confinement

  2. Assessment of depression

    Time frame: 1 day

    Assessment of depression by self-administered questionnaire before / during confinement

  3. Craving modification evaluation

    Time frame: 1 day

    Craving modification evaluation

Sponsors and collaborators

Lead sponsor

University Hospital, Montpellier

Other

Registry information

Official study title

Changes in the Consumption of Psychoactive Substances by People Incarcerated at the Villeneuve-Lès-Maguelone Prison During Containment Linked to COVID-19.

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
May 8, 2020
Registry last updated
Dec 29, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.